抗凝与抗血小板药物对B型主动脉夹层TEVAR术后主动脉重塑无不良影响
基于Vascular Quality Initiative TEVAR注册数据(2012-2020)回顾性分析1210例B型主动脉夹层患者,比较出院时使用与未使用抗凝药物者的主动脉再干预、假腔完全血栓形成及全因死亡。中位随访21.2个月,两组在18个月时上述终点均无差异,Cox回归显示抗凝使用与假腔完全血栓形成、再干预及死亡均无独立关联,二次分析提示抗血小板药物同样不影响上述结局。
要点
- 抗凝药物未增加TEVAR术后主动脉再干预或死亡风险,也未妨碍假腔完全血栓形成。
- 抗血小板药物对再干预、假腔血栓形成及死亡率同样无显著影响。
- B型主动脉夹层TEVAR术后使用抗凝或抗血小板药物不损害中期主动脉重塑与生存。
核心结论
- 抗凝和抗血小板药物似乎不会对B型主动脉夹层TEVAR术后的主动脉再干预或死亡等中期终点产生负面影响,也未损害假腔完全血栓形成。
研究设计与样本
- 回顾性队列研究,基于Vascular Quality Initiative TEVAR注册数据库(2012-2020)中因B型主动脉夹层接受TEVAR的患者。
- 共纳入1210例患者,平均年龄60.7±12.2岁,男性825例(68%),平均随访21.2±15.7个月(范围1-94个月)。
- 二次分析评估未使用抗凝药物患者中抗血小板治疗对结局的影响,采用Cox比例风险模型估计效应。
主要发现
- 抗凝组患者年龄更大(平均65.5岁 vs 60岁,P<.001),白人比例更高(69% vs 55%,P=.003),冠心病(10% vs 3%,P<.001)、充血性心力衰竭(10% vs 2%,P<.001)和慢性阻塞性肺疾病(15% vs 9%,P=.017)比例更高。
- 两组术前胸主动脉平均直径及使用的覆膜支架数量无差异。
- 18个月时,抗凝组与非抗凝组的主动脉再干预率(8% vs 9%,log-rank P=.873)、假腔完全血栓形成率(52% vs 45%,P=.175)和死亡率(2.5% vs 2.7%,P=.209)均相似。
- Cox回归控制协变量后,抗凝使用与假腔完全血栓形成率降低(HR 0.74,95%CI 0.5-1.1,P=.132)、主动脉再干预需求增加(HR 1.02,95%CI 0.62-1.68,P=.934)及死亡(HR 1.25,95%CI 0.64-2.47,P=.514)均无独立关联。
- 二次分析显示抗血小板药物不影响主动脉再干预率、假腔完全血栓形成率和死亡率。
临床怎么用
- B型主动脉夹层TEVAR术后患者因合并症需要抗凝或抗血小板治疗时,无需担心其损害主动脉重塑或增加中期不良事件。
- 抗凝治疗未妨碍假腔完全血栓形成,不应作为推迟或停止抗凝的理由。
局限性
- 回顾性注册研究设计,存在选择偏倚和未测量混杂因素可能。
- 随访时间中期(平均21.2个月),缺乏长期结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is a lack of evidence regarding the effect of anticoagulation and antiplatelet medications on aortic remodeling for aortic dissection after endovascular repair. We investigated whether anticoagulation and antiplatelet medications affect aortic remodeling after thoracic endovascular aortic repair (TEVAR) for type B aortic dissection (TBAD). METHODS: Records of the Vascular Quality Initiative TEVAR registry (2012-2020) were reviewed. Procedures performed for TBAD were included. Aortic reintervention, false lumen thrombosis of the treated aorta, and all-cause mortality at follow-up were compared between patients treated with and without anticoagulation medications. A secondary analysis was performed to assess the effect of antiplatelet therapy in patients not on anticoagulation. Cox proportional hazards models were used to estimate the effect of anticoagulation and antiplatelet therapies on outcomes. RESULTS: A total of 1210 patients (mean age, 60.7 ± 12.2 years; 825 males [68%]) were identified with a mean follow-up of 21.2 ± 15.7 months (range, 1-94 months). One hundred sixty-six patients (14%) were on anticoagulation medications at discharge and at follow-up. Patients on anticoagulation were more likely to be older (mean age, 65.5 vs 60 years; P < .001) and Caucasian (69% vs 55%; P = .003), with higher proportions of coronary artery disease (10% vs 3%; P < .001), congestive heart failure (10% vs 2%; P < .001), and chronic obstructive pulmonary disease (15% vs 9%; P = .017). There were no differences in the mean preoperative thoracic aortic diameter or the number of endografts used. At 18 months, the rates of aortic reinterventions (8% vs 9%; log-rank P = .873), complete false lumen thrombosis (52% vs 45%; P = .175), and mortality (2.5% vs 2.7%; P = .209) were similar in patients with and without anticoagulation, respectively. Controlling for covariates with the Cox regression method, anticoagulation use was not independently associated with a decreased rates of complete false lumen thrombosis (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.5-1.1; P = .132), increased need for aortic reinterventions (HR, 1.02; 95% CI, 0.62-1.68; P = .934), and mortality (HR, 1.25; 95% CI, 0.64-2.47; P = .514). On a secondary analysis, antiplatelet medications did not affect the rates of aortic reintervention, complete false lumen thrombosis, and mortality. CONCLUSIONS: Anticoagulation and antiplatelet medications do not appear to negatively influence the midterm endpoints of aortic reintervention or death in patients undergoing TEVAR for TBAD. Moreover, it did not impair complete false lumen thrombosis. Anticoagulation and antiplatelet medications do not adversely affect aortic remodeling and survival in this population at midterm.
引用
- Chang H, Rockman CB, Cayne NS, et al. Anticoagulation and antiplatelet medications do not affect aortic remodeling after thoracic endovascular aortic repair for type B aortic dissection. J Vasc Surg. 2021. PMID: 34182028. doi:10.1016/j.jvs.2021.05.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。